信达生物：与礼来公司达成战略合作，推进肿瘤及免疫领域创新药物的全球研发

Core Viewpoint - The company has entered into a strategic collaboration with Eli Lilly to advance global research and development of innovative drugs in the oncology and immunology fields, which includes significant financial incentives and revenue-sharing opportunities [1] Group 1: Financial Terms - The company will receive an upfront payment of $350 million as part of the agreement [1] - The company is eligible for up to approximately $8.5 billion in milestone payments related to research, regulatory, and commercialization achievements [1] - The company will also have the right to receive a tiered sales share based on net sales outside of Greater China for each product [1]